Vivos Therapeutics Profit Margin

The latest profit margin for VVOS is -128.0% as of March 2026. That compares with -76.82% in the prior-year period — down 66.6% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Vivos Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, VVOS's profit margin moved from -76.82% to -128.0% — a 66.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vivos Therapeutics's valuation or profitability profile.

Against Healthcare companies, VVOS currently prints -128.0% for profit margin, while the sector average sits near 15.29%. That is roughly 937.0% below the sector mean. Large gaps often invite a closer look at Vivos Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Vivos Therapeutics converts resources into returns. At -128.0%, VVOS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -76.82% in the prior-year period — down 66.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting VVOS's profit margin (-128.0%), review year-over-year change from -76.82%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.